Daxor Targets Nephrology Market with Blood Volume Analysis Platform at ASN Kidney Week 2026
Event summary
- Daxor will exhibit its FDA-cleared Blood Volume Analysis (BVA) platform at ASN Kidney Week 2026 in Denver, October 21–25, 2026.
- BVA technology aims to address fluid management challenges in complex kidney care, including cardiorenal syndrome and dialysis volume management.
- Daxor will engage with international nephrology leaders to advance precision medicine for renal disease patients.
- The company will provide live platform overviews, discuss clinical integration, and review reimbursement pathways at Booth #390.
The big picture
Daxor's participation in ASN Kidney Week 2026 underscores the growing importance of precise fluid management in nephrology. The event provides a critical platform for Daxor to showcase its BVA technology to a global audience of kidney care professionals, potentially expanding its market reach. The focus on data-driven precision medicine aligns with broader industry trends toward personalized treatment approaches in renal disease management.
What we're watching
- Market Expansion
- Whether Daxor can leverage ASN Kidney Week 2026 to accelerate adoption of BVA technology among nephrology professionals.
- Clinical Integration
- The pace at which Daxor can integrate its BVA platform into standard nephrology care protocols.
- Reimbursement Pathways
- How Daxor's discussions on reimbursement pathways will impact the commercial viability of its BVA technology.
